Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06615401 · ClinicalTrials.gov registry record
Understanding Perceived Access and Receipt of Gender-affirming Treatments Among Transgender Veterans
A clinical trial, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- 986
- Enrollment target
NCT06615401: Completed study, sponsored by VA Office of Research and Development.
NCT06615401 is a clinical trial that has completed, run by VA Office of Research and Development. The registered enrollment target is 986 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06615401 has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- 986 participants
- Enrollment target
Study Summary
Transgender Veterans (trans Vets) frequently experience gender dysphoria or distress related to discord between their gender identity and birth sex. Gender-affirming treatments (GATs) are medically necessary treatments to reduce gender dysphoria. However, not much is known about the barriers and facilitators that influence GAT access and receipt in VA and VA Community Care (CC), among trans Vets who desire GATs. The goals of this mixed-methods study are to determine which GATs trans Vets receive and in which setting, identify barriers and facilitators associated with desired GAT receipt in VA and CC, examine association of GAT receipt, specifically mental healthcare and hormone therapy, with mental health and suicide risk and understand trans Vet experiences related to receipt and desire for mental healthcare and hormone therapy in VA and CC.
Primary Outcome
Through a national survey, the investigators will identify receipt of gender-affirming treatment in VA and VA Community Care among transgender and gender diverse Veterans.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 986 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2025-01-18 |
What the finished NCT06615401 record still lists
NCT06615401 is an observational study that tracks outcomes without assigning an intervention. The registered 986 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT06615401 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06615401 about?
NCT06615401 is a clinical study titled "Understanding Perceived Access and Receipt of Gender-affirming Treatments Among Transgender Veterans". Transgender Veterans (trans Vets) frequently experience gender dysphoria or distress related to discord between their gender identity and birth sex. Gender-affirming treatments (GATs) are medically necessary treatments to reduce gender dysphoria. However, not much is known about the barriers and fac...
What is the current status of trial NCT06615401?
This trial is currently completed. The enrollment target is 986 participants. The study started on 2024-10-01. Estimated completion is 2025-01-18.
Who is sponsoring clinical trial NCT06615401?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05079841 · 988 participants · Phase 4
The Stimulation To Induce Mothers Study
- NCT05441709 · 990 participants · NA
Furthering Equity Through Infant Feeding EDucation and Support
- NCT06340646 · 990 participants · NA
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
- NCT06878261 · 990 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI